• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 27, 2023
Politics, Policy & Law

Oct. 27 Quick Takes: AbbVie pegs IRA cost at $2.1 billion

Plus: FDA approves Coherus’ PD-1 mAb based on China data, and updates from Otsuka, Sernova, Lilly, Roche and more
Read More
BioCentury | Jun 16, 2023
Deals

Surface accepts buyout; deal helps Coherus build innovative pipeline

Nine-year-old immuno-oncology company’s value had dwindled since deprioritizing CD47 program, entering GSK deal
Read More
BioCentury | Jan 7, 2022
Distillery Therapeutics

IL-27 producing B regulatory cells for autoimmune disease

Read More
BioCentury | Sep 29, 2020
Distillery Therapeutics

Blocking glucocorticoid signaling to increase checkpoint inhibitor sensitivity

DISEASE CATEGORY: Cancer
INDICATION: Melanoma; colorectal cancer Inhibiting the glucocorticoid receptor could treat melanoma and colorectal cancer and enhance sensitivity to checkpoint
Read More
BioCentury | Dec 21, 2018
Company News

Surface drops after deprioritizing lead product

Read More
BioCentury | Dec 19, 2018
Company News

Surface drops after deprioritizing lead product

Read More
BioCentury | Oct 18, 2017
Translation in Brief

Neutrophil bias

How modulation of neutrophils by IL-27 could treat stroke
Read More
BioCentury | Sep 26, 2017
Distillery Therapeutics

Neurology

Read More
BioCentury | Jul 9, 2015
Targets & Mechanisms

Top Translational Targets, 2013-14

Read More
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Autoimmune disease

Read More
Items per page:
1 - 10 of 17
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa